TheStreet Biotech (@TSTbiotech) header
TheStreet Biotech (@TSTbiotech) profile picture

TheStreet Biotech

@TSTbiotech

News affecting the biotech industry and associated stocks. Includes #biotech trends, market analysis as well as mergers and acquisition news. cc: @TheStreet

 New York, NY
thestreet.com/headlines-and-perspectives/biotech/index.html?cm_ven_int=subnavnews
Joined October 2011
  • Tweets2K
  • Following49
  • Followers5.7K
729Media
Photo by TheStreet Biotech (@TSTbiotech)Photo by TheStreet Biotech (@TSTbiotech)Photo by TheStreet Biotech (@TSTbiotech)Photo by TheStreet Biotech (@TSTbiotech)Photo by TheStreet Biotech (@TSTbiotech)Photo by TheStreet Biotech (@TSTbiotech)Photo by TheStreet Biotech (@TSTbiotech)Photo by TheStreet Biotech (@TSTbiotech)Photo by TheStreet Biotech (@TSTbiotech)Photo by TheStreet Biotech (@TSTbiotech)
New home for @TheStreet's #biotech news. Includes trends, market analysis as well as mergers and acquisition news.
3
6
14
Celgene, Agios Expand, Amend Cancer Drug Partnership dlvr.it/LLSGFV
Image from TheStreet Biotech (@TSTbiotech)
61
17
Heron and the never-ending FDA drug review dlvr.it/LLRmZR
Image from TheStreet Biotech (@TSTbiotech)
1
47
14
Heron and the never-ending FDA drug review dlvr.it/LLNbYj
Image from TheStreet Biotech (@TSTbiotech)
1
54
7
Celgene, Agios Expand, Amend Cancer Drug Partnership dlvr.it/LL17gk
Image from TheStreet Biotech (@TSTbiotech)
53
11
Investors comforted as Perrigo sticks to forecast dlvr.it/LKx9q0
Image from TheStreet Biotech (@TSTbiotech)
56
7
$REGN spike not tied to $PFE's $ANAC deal, but it doesn't hurt dlvr.it/LKYmNy
Image from TheStreet Biotech (@TSTbiotech)
65
11
Pfizer beats Allergan to excema-drugmaker Anacor for $5.2B dlvr.it/LKTpTn
Image from TheStreet Biotech (@TSTbiotech)
62
7
Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study dlvr.it/LKS1fy
Image from TheStreet Biotech (@TSTbiotech)
58
8
Pfizer Buying Anacor in $5.2 Billion Cash Deal dlvr.it/LKNMtF
Image from TheStreet Biotech (@TSTbiotech)
47
12
$MDVN shares stand pat amid further bid speculation dlvr.it/LJR9kW
Image from TheStreet Biotech (@TSTbiotech)
51
9
$MYL tacks on another generics company on the cheap dlvr.it/LJKvns
Image from TheStreet Biotech (@TSTbiotech)
40
8
Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk should not be trusted $XON dlvr.it/LJCHFD
Image from TheStreet Biotech (@TSTbiotech)
59
1
12
New regime at $PRGO provides reason to invest dlvr.it/LHxJV8
Image from TheStreet Biotech (@TSTbiotech)
60
10
Cramer says buy $DOW & $DD over $MON in seed business dlvr.it/LHtcG3
Image from TheStreet Biotech (@TSTbiotech)
41
13
Mast (mstx) sickle cell drug seeks to defy long odds like leicester city dlvr.it/LHmxLP
Image from TheStreet Biotech (@TSTbiotech)
53
13
DOJ investigation has little impact on pharmas' share prices dlvr.it/LHR5s7
Image from TheStreet Biotech (@TSTbiotech)
49
1
6
Global bidding war seen for Medivation dlvr.it/LHPJB9
Image from TheStreet Biotech (@TSTbiotech)
54
13
Cramer sees more upside in $AGN dlvr.it/LGxWSv
Image from TheStreet Biotech (@TSTbiotech)
51
8
$AGN authorizes $10 billion buy back, beats estimates dlvr.it/LGslpr
Image from TheStreet Biotech (@TSTbiotech)
57
6
CytRx bear thesis explained: why sarcoma drug trial will fail dlvr.it/LGs5kh
Image from TheStreet Biotech (@TSTbiotech)
52
10
Load more